Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

NCT00462553 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: sunitinib malate
DRUG: gemcitabine hydrochloride

Sponsor

National Cancer Institute (NCI)